ELCA™ CORONARY LASER AHERECTOMY CATHETER
Treatment Versatility for Coronary Interventions
ELCA™ CORONARY LASERATHERECTOMY CATHETER

Proven Technology

• Treating patients for more than 20 years
• Optimally spaced fibers for improved performance
• Adjustable laser energy settings to satisfy many clinical needs
• Automatic shut-off feature for advanced patient safety

Advanced Performance

• Saline infusion improves safety outcomes
• Slow advancement increases luminal gain
• Two-thirds vessel sizing rule for predictable outcomes
• Concentric and eccentric tip designs for lesion-specific treatment

Larger luminal gain with slow advancement

3 Data on file at Spectranetics.
Recanalize Occluded Arteries
Change Lesion Morphology
Optimize Treatment Options

Broad Range of Indications
- Total occlusions traversable by a guidewire
- Occluded SVGs
- Ostial lesions
- Moderately calcified stenoses
- Long lesions (>20mm)
- Lesions which previously failed PTCA
- Restenosis in 316L stainless steel stents prior to brachytherapy
Contraindications

- Lesion is located within a bifurcation.
- Guidewire cannot be passed through the lesion.
- Lesion is beyond acute bends or is in a location within the coronary anatomy where the catheter cannot traverse.
- Guide wire cannot be passed through the lesion.
- Lesion is located within a bifurcation.
- Patient is not an acceptable candidate for bypass graft surgery.

These lesions must be traversable by a guidewire and composed of atherosclerotic plaque and/or calcified material. The lesions should be well defined by angiography.

**ELCA™ Indications**

The Laser Catheters are intended for use either as a stand-alone modality or in conjunction with Percutaneous Transluminal Coronary Balloon Angioplasty (PTCA) surgery. The following Indications for Use, Contraindications and Warnings have been established through multicenter clinical trials. The Spectranetics CVX-300® Excimer Laser System and the multifiber laser catheter models are safe and effective for the following indications:

- Occluded saphenous vein bypass grafts.
- Ostial lesions.
- Long lesions—(greater than 20mm in length).
- Moderately calcified stenoses.
- Total occlusions traversable by a guidewire.
- Lesions which previously failed balloon angioplasty.
- Restenosis in 316L stainless steel stents, prior to the administration of intravascular brachytherapy.

These lesions must be traversable by a guidewire and composed of atherosclerotic plaque and/or calcified material. The lesions should be well defined by angiography.

**Important Safety Information**

**ELCA™ Indications**

The Laser Catheters are intended for use either as a stand-alone modality or in conjunction with Percutaneous Transluminal Coronary Balloon Angioplasty (PTCA) surgery. The following Indications for Use, Contraindications and Warnings have been established through multicenter clinical trials. The Spectranetics CVX-300® Excimer Laser System and the multifiber laser catheter models are safe and effective for the following indications:

- Occluded saphenous vein bypass grafts.
- Ostial lesions.
- Long lesions—(greater than 20mm in length).
- Moderately calcified stenoses.
- Total occlusions traversable by a guidewire.
- Lesions which previously failed balloon angioplasty.
- Restenosis in 316L stainless steel stents, prior to the administration of intravascular brachytherapy.

These lesions must be traversable by a guidewire and composed of atherosclerotic plaque and/or calcified material. The lesions should be well defined by angiography.

**Contraindications**

- Lesion is in an unprotected left main artery.
- Lesion is beyond acute bends or is in a location within the coronary anatomy where the catheter cannot traverse.
- Guide wire cannot be passed through the lesion.
- Lesion is located within a bifurcation.
- Patient is not an acceptable candidate for bypass graft surgery.

See complete IFU for more information before attempting use of ELCA.

**Warnings**

Federal (USA) law restricts this device to sale by or on the order of a physician with appropriate training. A clinical investigation of the Spectranetics CVX-300® Excimer Laser System did not demonstrate safety and effectiveness in lesions amenable to routine PTCA or those lesions not mentioned in the Indications for Use, above. The effect of adjunctive balloon angioplasty on restenosis, as opposed to laser alone, has not been studied. The use of the CVX-300® Excimer Laser System is restricted to physicians who are trained in the use of the product.

**Precautions**

This device has been sterilized using Ethylene Oxide and is supplied STERILE. The device is designated and intended for SINGLE USE ONLY and must not be resterilized and/or reused. Store in a cool, dry place. Protect from direct sunlight and high temperatures (greater than 60°C or 140°F). During the procedure, appropriate anticoagulant and coronary vasodilator therapy must be provided to the patient. Anticoagulant therapy should be administered per the institution's PTCA protocol for a period of time to be determined by the physician after the procedure. Percutaneous Excimer Laser Coronary Atherectomy (ELCA) should be performed only at hospitals where emergency coronary bypass graft surgery can be immediately performed in the event of a potentially injurious or life-threatening complication. The results of clinical investigation indicated that patients with the following conditions are at a higher risk for experiencing acute complications:

- Patients with diabetes.
- Patients with a history of smoking.
- Lesions with tortuous vessels.

**Spectranetics**

Always Reaching Farther

---

**Corporate Headquarters**

The Spectranetics Corporation
9965 Federal Dr., Colorado Springs, CO 80921
Tel: 719-447-2000 • Fax: 719-447-2022
Customer Service: 800-231-0978

**Spectranetics International B.V.**

Plesmanstraat 6, 3833 LA Leusden
The Netherlands
Tel: +31 33 4347 050
Fax: +31 33 4347 051

**German Office**

Spectranetics Deutschland GmbH
Schweinfurter Str. 7
97080 Würzburg
Germany
Tel: +49 931 4520080 • Fax: +49 931 45200811

©2015 Spectranetics All rights reserved. Approved for external distribution. D0019184-03 012015